Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade

Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Klepsch, Victoria, Hermann-Kleiter, Natascha, Do-Dinh, Patricia, Jakic, Bojana, Offermann, Anne, Efremova, Mirjana, Sopper, Sieghart, Rieder, Dietmar, Krogsdam, Anne, Gamerith, Gabriele, Perner, Sven, Tzankov, Alexandar, Trajanoski, Zlatko, Wolf, Dominik, Baier, Gottfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906604/
https://www.ncbi.nlm.nih.gov/pubmed/29670099
http://dx.doi.org/10.1038/s41467-018-04004-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906604/
https://www.ncbi.nlm.nih.gov/pubmed/29670099
http://dx.doi.org/10.1038/s41467-018-04004-2

Ejemplares similares